• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Fat Tail Daily

Investment Ideas From the Edge of the Bell Curve

  • Menu
    • Commodities
      • Resources and Mining
      • Copper
      • Gold
      • Iron Ore
      • Lithium
      • Silver
      • Graphite
      • Rare Earths
    • Technology
      • AI
      • Bitcoin
      • Cryptocurrency
      • Energy
      • Financial Technology
      • Bio Technology
    • Market Analysis
      • Latest ASX News
      • Dividend Shares
      • ETFs
      • Stocks and Bonds
    • Macro
      • Australian Economy
      • Central Banks
      • World Markets
    • Small Caps
    • More
      • Investment Guides
      • Premium Research
      • Editors
      • About
      • Contact Us
  • Latest
  • Fat Tail Series
  • About Us
Technology Bio Tech

MGC Pharmaceuticals Share Price Up on Order Announcement (ASX:MXC)

Like 0

By Kiryll Prakapenka, Thursday, 30 September 2021

MGC Pharmaceuticals Ltd [ASX:MXC] share price is currently up 6.90%. The MGC Pharmaceuticals Ltd [ASX:MXC] announced that its distribution partner placed an order for 1,000 units of MXC’s CimetrA on an expedited basis.

The MGC Pharmaceuticals Ltd [ASX:MXC] announced that its distribution partner placed an order for 1,000 units of MXC’s CimetrA on an expedited basis.

The units were ordered to fast track the approval process for the medication to be distributed and sold in the US.

The expedited order buoyed the market. MGC Pharmaceuticals Ltd [ASX:MXC] share price is currently up 6.90%.

ASX MXC - MGC Share Price ChartSource: Tradingview.com

Let’s look at today’s announcement in detail and see what can possibly be next for MXC shares.

AMC Holdings orders 1,000 units of CimetrA

AMC — MGC Pharma’s distribution partner — placed an initial order for 1,000 units of CimetrA.

CimetrA is the pharmaceutical version of MXC’s nutraceutical-branded product, ArtemiC.

MXC says CimetrA is anti-inflammatory and can reduce the hyper-inflammatory response seen in some COVID-19 patients, known as ‘cytokine storm’.

The units will be shipped to a Tampa area pharmacy where they will be analysed.

It marks the first step in undertaking a material commercial order of MGC Pharma products as discussed under the US Supply Agreement signed by both the parties in August 2021.

Both MXC and AMC are also working to formalise their business and research partnership and are ‘confident they remain on track to do so.’

Discover our top three ASX-listed pot stocks in 2021. Click here to learn more.

Additionally, AMC is currently working with the University of Florida in Tampa and the Holy Cross Hospital in Fort Lauderdale to submit CimetrA and CogniCann to their respective Internal Review Boards for approval.

Brent Yessin, General Counsel for AMC, made his case for a viable COVID-19 treatment product:

‘As the US endures a COVID spike, keeping COVID positive patients out of the hospital has become a major policy objective of countless state Governors and their health departments.

‘For every 1000 patients who are treated effectively and kept out of hospital, the state or healthcare systems save US$40M, a rare instance where clinical and financial imperatives are perfectly harmonized.’

What’s next for the MXC Share Price?

Today’s update follows MXC’s CannEpil+ product to treat refractory epilepsy, gaining approval for UK import.

MGC Pharma was also recently granted a permit to import its proposed COVID-19 treatment to India for emergency use drug registration.

Bottom line is that MXC is moving quickly on multiple fronts.

What’s next for the bio-pharma stock?

US-based clinical trials are being established for MGC Pharma’s phytomedicine products in Florida, Texas, the NYC area, and Kentucky and are expected to commence in Q4 2021.

Meaning investors can expect more developments from the stock in the near term.

MGC Pharma CEO and Managing Director Roby Zomer said:

‘AMC are already making significant progress in propelling CimetrA, CannEpil and CogniCann® to Clinical Trial stage in the US and we are pleased that they have cemented relationships with these prestigious institutions for the continued research into our products.’

Now, if you are interested in more small-cap stocks with exciting potential, I suggest checking out this report by our small-cap analyst Ryan Clarkson-Ledward.

The report takes you through four companies Ryan believes are small-cap gems.

Regards,

Kiryll Prakapenka,

For Money Morning

PS: Our publication Money Morning is a fantastic place to start on your investment journey. We talk about the big trends driving the most innovative stocks on the ASX. Learn all about it here

All advice is general advice and has not taken into account your personal circumstances.

Please seek independent financial advice regarding your own situation, or if in doubt about the suitability of an investment.

Kiryll Prakapenka

Kiryll’s Premium Subscriptions

Publication logo
Fat Tail Investment Research

Latest Articles

  • Google Search Isn’t Dead, It Just Smells Funny
    By Charlie Ormond

    The question isn't whether this disruption will happen, but whether you're positioned to profit from it.

  • Trump sparks uranium rally
    By Callum Newman

    Tune in today to watch the latest Closing Bell podcast with Murray Dawes. We discuss the outlook for US stocks, uranium, RBA “bulltish”…plus discuss a few stocks. Tune in now!

  • Markets on Edge? Who cares, this Explorer just delivered a 1,600m Hit
    By James Cooper

    James Cooper outlines the potential opportunities among explorers making major drill hits, but aren’t capturing attention from investors, yet.

Primary Sidebar

Latest Articles

  • Google Search Isn’t Dead, It Just Smells Funny
  • Trump sparks uranium rally
  • Markets on Edge? Who cares, this Explorer just delivered a 1,600m Hit
  • Just “ChatGPT It”, Stupid
  • The blunder that cost Australia $28 billion

Footer

Fat Tail Daily Logo
YouTube
Facebook
x (formally twitter)
LinkedIn

About

Investment ideas from the edge of the bell curve.

Go beyond conventional investing strategies with unique ideas and actionable opportunities. Our expert editors deliver conviction-led insights to guide your financial journey.

Quick Links

Subscribe

About

FAQ

Terms and Conditions

Financial Services Guide

Privacy Policy

Get in Touch

Contact Us

Email: support@fattail.com.au

Phone: 1300 667 481

All advice is general in nature and has not taken into account your personal circumstances. Please seek independent financial advice regarding your own situation, or if in doubt about the suitability of an investment.

The value of any investment and the income derived from it can go down as well as up. Never invest more than you can afford to lose and keep in mind the ultimate risk is that you can lose whatever you’ve invested. While useful for detecting patterns, the past is not a guide to future performance. Some figures contained in our reports are forecasts and may not be a reliable indicator of future results. Any actual or potential gains in these reports may not include taxes, brokerage commissions, or associated fees.

Fat Tail Logo

Fat Tail Daily is brought to you by the team at Fat Tail Investment Research

Copyright © 2025 Fat Tail Daily | ACN: 117 765 009 / ABN: 33 117 765 009 / ASFL: 323 988